Ordinal Scale – Page 2 – Communicable Diseases Research

Development and Validation of a Treatment Benefit Index to Identify Hospitalized Patients With COVID-19 Who May Benefit From Convalescent Plasma

회복기 혈장의 혜택을 받을 수 있는 COVID-19 입원 환자를 식별하기 위한 치료 혜택 지수의 개발 및 검증

Research

Published on 2022-01-252022-09-12
Journal: JAMA Network Open [Category] SARS, 진단,

Baseline procalcitonin as a predictor of bacterial infection and clinical outcomes in COVID-19: A case-control study

COVID-19의 박테리아 감염 및 임상 결과의 예측 인자로서 기준선 프로 칼시토닌 : 사례 관리 연구

Observational Study

Published on 2022-01-132022-09-10
Journal: PLoS ONE [Category] SARS, 바이오마커, 임상,

[키워드] Acute respiratory failure acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus-2 Adult patient assist Bacteremia Bacterial Bacterial infection bacterial pneumonia bacterial superinfection baseline Biomarkers Boston Care case-control study Clinical outcome clinical symptom Clinical symptoms coronavirus coronavirus disease Coronavirus-2 COVID-19 Culture diagnosed electronic medical records evaluate Infection inflammatory biomarkers laboratory data management medical records nasopharyngeal NIAID Ordinal Scale outcome Patient Patient management patients hospitalized patients with COVID-19 PCR PCT Pneumonia positive positively correlated predict procalcitonin respiratory Respiratory failure Result SARS-CoV-2 SARS-COV-2 infection Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus significantly higher survival treated Urinalysis were excluded
[DOI] 10.1371/journal.pone.0262342 PMC 바로가기 [Article Type] Observational Study

Evaluation of new or repurposed treatments for COVID-19: protocol for the phase Ib/IIa DEFINE trial platform

COVID-19에 대한 신규 또는 용도 변경 치료제 평가: Ib/IIa상 DEFINE 시험 플랫폼 프로토콜

Article

Published on 2021-12-152022-09-11
Journal: BMJ Open [Category] 임상,

[키워드] acceptance adaptive administration Analysis Appropriate approval Arm ARMS assisted ventilation caused changes in clinical trial Coagulation Cohort Community Complete computer COVID-19 COVID-19 therapy dependent on development during treatment effective Efficacy Ethics ethics committee EudraCT Evidence evidence of Experimental medicine exploratory Follow-up hospital Hospital stay hospitalised patient Infection Infectious diseases information initial mechanism mechanism of action Medicine MHRA National Health Service NEWS2 NHS Novel coronavirus Open-label Ordinal Scale oxygen Oxygen requirements participant Pathways Patient patient cohorts patient safety patients with COVID-19 peer-reviewed pharmacokinetic Pneumonia Pneumonitis positive present product protocol randomisation randomised Randomised Evaluation REC recovery recruited recruitment registration number research and development Research Ethics Research Ethics Committee respiratory medicine (see thoracic medicine) Safe SARS-CoV-2 score secondary Standard of care statistical analysis submitted Support Therapeutics therapy Thoracic Treatment treatment arm treatment period Trial trial platform variable Viral load viral-induced WHO ordinal scale
[DOI] 10.1136/bmjopen-2021-054442 PMC 바로가기 [Article Type] Article

Effect of High-Flow Oxygen Therapy vs Conventional Oxygen Therapy on Invasive Mechanical Ventilation and Clinical Recovery in Patients With Severe COVID-19: A Randomized Clinical Trial

중증 COVID-19 환자의 침습성 기계 환기 및 임상 회복에 대한 고유량 산소 요법 대 기존 산소 요법의 효과: 무작위 임상 시험

Randomized Controlled Trial

Published on 2021-12-072022-09-11
Journal: JAMA [Category] SARS, 임상, 치료기술,

[키워드] 7-category ordinal scale 95% CI adjusted age Analysis assigned Bacteremia Bacterial bacterial pneumonia calculated clinical clinical recovery clinical trial Comorbidities conducted Conventional COVID-19 Cox proportional hazard Cox proportional hazards model determine distress Effect Endotracheal intubation Follow-up fraction hazard ratio High-flow oxygen high-flow oxygen therapy hospital Hypoxemia Identifier intensive care unit intubation IQR less low-flow oxygen therapy Mechanical mechanical ventilation support median age median time nasal nasal cannula occurred Open-label Ordinal Scale outcome oxygen Oxygen therapy partial pressure partial pressure of arterial oxygen Patient patients randomized Pneumonia proportional hazards model Randomized randomized patients Randomly receive respiratory distress severe COVID-19 severity significantly Suspected Treatment women
[DOI] 10.1001/jama.2021.20714 PMC 바로가기 [Article Type] Randomized Controlled Trial

Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of Care

중증 코로나바이러스 감염증 2019(COVID-19)에 대한 렘데시비르 대 치료 표준을 받는 코호트

Clinical Trial

Published on 2021-12-062022-09-11
Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 임상, 치료제,

[키워드] 95% CI 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adjusted odds ratio Analysis Antiviral antiviral agent Antiviral treatment clinical Clinical outcome clinical outcomes clinical status Comparative analysis coronavirus coronavirus disease Coronavirus disease 2019 Course COVID-19 criteria death dichotomized died Efficacy greater Hospitalized inclusion criteria Infection Mortality multivariable logistic regression Open-label open-label trial Ordinal Scale oxygen oxygen saturation Patient Phase 3 primary endpoint Probability proportion pulmonary infiltrates Randomized receiving reduced Remdesivir required retrospective cohort retrospective cohort study room air SARS-CoV-2 secondary endpoint severe acute respiratory syndrome Coronavirus severe coronavirus disease severe COVID-19 significantly Standard Standard of care Standard-of-care supplemental oxygen treated Treatment Trial was used Weighting
[DOI] 10.1093/cid/ciaa1041 PMC 바로가기 [Article Type] Clinical Trial

A multi-centre, randomized, double-blind, placebo-controlled clinical trial of the efficacy and safety of chloroquine phosphate, hydroxychloroquine sulphate and lopinavir/ritonavir for the treatment of COVID-19 in Lagos State: study protocol for a randomized controlled trial

라고스 주에서 COVID-19 치료를 위한 인산클로로퀸, 황산히드록시클로로퀸 및 로피나비르/리토나비르의 효능과 안전성에 대한 다기관, 무작위, 이중 맹검, 위약 대조 임상 시험: 무작위 대조 시험을 위한 연구 프로토콜

Study Protocol

Published on 2021-12-042022-09-10
Journal: Trials [Category] SARS, 임상,

[키워드] 2019-nCoV 7-point ordinal scale acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 added African allocation Analysis blinded caused China Chloroquine Chloroquine phosphate clinical clinical status clinician Clinicians coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 disease Critical Data analysis develop disease double-blind drug effective Efficacy Efficacy and safety Health Health Organization Hydroxychloroquine hydroxychloroquine sulphate identity intention-to-treat Intervention Lago Lagos lead Lopinavir Lopinavir/ritonavir management Mathematical modelling measure Ministry of Health National Nigeria Ordinal Scale outcome measures Pan pandemic participant Participants Patient patients with COVID-19 phosphate placebo-controlled placebo-controlled clinical trial Primary outcome R software Randomized Randomized controlled trial Research respiratory Ritonavir SARS-CoV-2 severe acute respiratory syndrome Coronavirus severity severity of illness Standard of care Standard therapy state statistical analysis Study protocol sulphate supplementary material team the disease treat Treatment Trial Trial registration World Health Organization Wuhan
[DOI] 10.1186/s13063-021-05675-x PMC 바로가기 [Article Type] Study Protocol

An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19

코로나19로 입원한 환자를 대상으로 한 로피나비르/리토나비르, 로피나비르/리토나비르 + IFN-β-1a 및 히드록시클로로퀸의 효과에 대한 공개 무작위 대조 시험

Clinical Trial

Published on 2021-12-012022-09-11
Journal: Clinical microbiology and infection : the official [Category] 임상, 치료제,

[키워드] 95% confidence interval 95%CI acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adaptive adjusted odds ratio adults hospitalized age analyses Arm ARMS clinical status conducted Controlled trial coronavirus coronavirus 2019 disease COVID-19 evaluated expected hospitalized patient Hydroxychloroquine Inpatient intention-to-treat population Interferon β-1a IQR Lopinavir LOPINAVIR AND RITONAVIR Lopinavir/ritonavir male median age multicentre no significant effect not improved Occurrence Open-label Ordinal Scale outcome oxygen participant pharmacokinetic plasma concentration Primary outcome quantification Randomized Randomized controlled trial regimen Remdesivir respiratory specimen respiratory specimens respiratory tract specimens Ritonavir SARS-CoV-2 SARS-CoV-2 clearance secondary Secondary outcomes Serious Adverse Event Serious Adverse Events seven-point ordinal scale severe acute respiratory syndrome Coronavirus severe disease significant effect significantly higher solidarity Solidarity trial Standard of care the median the WHO treat Treatment Trial trough ventilatory support Virological with COVID-19
[DOI] 10.1016/j.cmi.2021.05.020 PMC 바로가기 [Article Type] Clinical Trial

ARCADIA study protocol: a phase II, randomised, double-blind, placebo-controlled clinical trial to assess the safety and efficacy of AZD1656 in patients with diabetes hospitalised with suspected or confirmed COVID-19

ARCADIA 연구 프로토콜: COVID-19가 의심되거나 확인된 당뇨병 환자를 대상으로 AZD1656의 안전성과 효능을 평가하기 위한 2상 무작위 이중 맹검 위약 대조 임상 시험

Article

Published on 2021-12-012022-09-11
Journal: BMJ Open [Category] SARS, 임상,

[키워드] 1:1 affected ARCADIA AZD1656 baseline bioethics case report form caused clinical Clinical and laboratory data Clinical improvement Clinical outcome clinical outcomes clinical trials collected Committee Complication COVID-19 Czech Republic death determine Device diabete diabetes disease severity double-blind East Efficacy Ethical approval Ethics ethics committee EudraCT general diabetes. global pandemic glucokinase Glucose glycaemic control help homeostasis hospital hospitalised Hypothesis immunological immunological mechanism IMPROVE improve clinical outcome improvement increased risk laboratory data Local maintain Medical devices Medicine Medicines Mortality National Health Service Ordinal Scale Patient patients patients with COVID-19 patients with diabete Placebo placebo tablet Placebo tablets placebo-controlled placebo-controlled clinical trial Prague primary endpoint randomised REC receive registration number Romania SARS-CoV-2 SARS-COV-2 infection scale South Sponsor Standard of care survival susceptibility the primary endpoint Trial type 2 diabete type 2 diabetes WHO with COVID-19
[DOI] 10.1136/bmjopen-2021-049650 PMC 바로가기 [Article Type] Article

Clinical and virological impact of single and dual infections with influenza A (H1N1) and SARS-CoV-2 in adult inpatients

성인 입원 환자에서 인플루엔자 A (H1N1) 및 SARS-COV-2에 대한 단일 및 이중 감염의 임상 및 바이러스 학적 영향

Research Article

Published on 2021-11-292022-09-10
Journal: PLoS Neglected Tropical Diseases [Category] MERS, SARS, 신종인플루엔자, 유전자 메커니즘, 진단, 치료기술,

[키워드] Acute heart failure Acute kidney injury acute respiratory syndrome acute respiratory syndrome coronavirus Admission admittance Adult patients adults hospitalized adverse event adverse events affected All participant All participants All the patient all the patients ARDS Bacterial infections baseline both virus both viruses caused China clinical Clinical outcome Clinical severity clinical status Clinical symptoms Co-infection Coinfection Comprehensive coronavirus COVID-19 pandemic Ct value Ct values demographic described diagnosis of COVID-19 diagnostics electronic medical record electronic medical records enrolled Epidemic Frequency future therapeutic groups Guangdong Guangzhou H1N1 H1N1 infection heart failure Hospitalization Hospitalized ICU incidence Infection Influenza influenza A initial Inpatient Inpatients laboratory data Lower mechanism median medical records molecular nasopharyngeal swabs Older age Ordinal Scale Patient patients patients hospitalized PCR cycle positively correlated Prevalence prevalence rate Prophylactic respiratory SAR-CoV-2 SARS-CoV-2 SARS-COV-2 infection score Seasonal influenza Secondary bacterial infections seven-category ordinal scale severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 severe disease significantly Symptom tested threshold trajectory Transmission Treatment Viral Viral load Viral RNA viral RNA detection Virological virus viruses were assessed with COVID-19
[DOI] 10.1371/journal.pntd.0009997 PMC 바로가기 [Article Type] Research Article

Treatment effect of nafamostat mesylate in patients with COVID-19 pneumonia: study protocol for a randomized controlled trial

COVID-19 폐렴 환자에서 나파모스타트 메실레이트의 치료 효과: 무작위 대조 시험을 위한 연구 프로토콜

Study Protocol

Published on 2021-11-232022-09-10
Journal: Trials [Category] MERS, SARS, 임상,

[키워드] adverse events Antibiotic therapy assigned category Clinical improvement clinical status clinical trial contribute control group COVID-19 COVID-19 pneumonia COVID-19 pneumonia patients defined discharge dose duration of hospitalization ECMO evaluate extracorporeal membrane oxygenation hospital Hydroxychloroquine Hypothesis IMPROVE incidence intervention group invasive Lopinavir Lopinavir/ritonavir Mortality mortality rate nafamostat Nafamostat mesilate National Early Warning Score Non-invasive non-invasive ventilation open Ordinal Scale oxygen Oxygen therapy Patient patients with COVID-19 Pneumonia Primary outcome proportion protocol Randomized Randomized controlled trial Randomly receive Ritonavir score secondary outcome seven-category ordinal scale severity Standard therapy Study protocol therapeutic effect therapeutic strategy therapy Time to improvement Trial registration Ventilation ventilator Viral Viral load with COVID-19
[DOI] 10.1186/s13063-021-05760-1 PMC 바로가기 [Article Type] Study Protocol